Lebenthal Asset Management buys $6,709,834 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Lebenthal Asset Management scooped up 21,389 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 148,975 shares of Abbott Laboratories which is valued at $6,709,834.Abbott Laboratories makes up approximately 0.84% of Lebenthal Asset Management’s portfolio.

Other Hedge Funds, Including , Quadrature Capital Ltd added ABT to its portfolio by purchasing 189,950 company shares during the most recent quarter which is valued at $8,555,348. Abbott Laboratories makes up approx 0.60% of Quadrature Capital Ltd’s portfolio.Thomaspartners boosted its stake in ABT in the latest quarter, The investment management firm added 344,292 additional shares and now holds a total of 3,902,475 shares of Abbott Laboratories which is valued at $175,689,425. Abbott Laboratories makes up approx 2.25% of Thomaspartners’s portfolio.Bailard boosted its stake in ABT in the latest quarter, The investment management firm added 3,687 additional shares and now holds a total of 10,336 shares of Abbott Laboratories which is valued at $465,637. Abbott Laboratories makes up approx 0.05% of Bailard’s portfolio.Public Employees Retirement Association Of Colorado reduced its stake in ABT by selling 21,875 shares or 6.67% in the most recent quarter. The Hedge Fund company now holds 306,252 shares of ABT which is valued at $13,704,777. Abbott Laboratories makes up approx 0.11% of Public Employees Retirement Association Of Colorado’s portfolio.Menlo Advisors boosted its stake in ABT in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 48,742 shares of Abbott Laboratories which is valued at $2,045,702. Abbott Laboratories makes up approx 1.71% of Menlo Advisors’s portfolio.

Abbott Laboratories closed down -0.27 points or -0.61% at $43.9 with 74,01,381 shares getting traded on Tuesday. Post opening the session at $44.37, the shares hit an intraday low of $43.9 and an intraday high of $44.42 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.